Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
NJ-founded MetasTx is advancing an NCI-backed diagnostic and next-gen KIT inhibitor for high-risk prostate cancer, aiming for 2026 validation.
-
MetasTx has been awarded a NCI SBIR grant for its integrated diagnostic and therapeutic platform aimed at predicting and preventing prostate cancer.
-
Dr. Chernoff’s decision to join the Board of Managers reflects his strong belief in MetasTx’s science and strategic direction.
-
MetasTx aims to revolutionize cancer treatment by targeting p21-activated kinase (PAK-1), a critical driver of metastasis in solid tumors.
-
Dr. David Crich, Georgia Research Alliance, and David Chu, Eminent Scholar In Drug Design and Head of Chemistry at MetasTx honored.
-
BASKING RIDGE, N.J., Aug. 29, 2022 (GLOBE NEWSWIRE) -- MetasTx LLC, a company driven to create novel therapeutics to treat and prevent metastasis of cancers, today announced that Jonathan Chernoff,...
-
BASKING RIDGE, N.J., June 07, 2022 (GLOBE NEWSWIRE) -- MetasTx LLC is driven to create novel therapeutics to treat and prevent metastasis of cancers. Harvey Homan, CEO and Co-Founder has...